Few patients abroad require more than three racks, but it is common in the country to have 5-10 racks, which are abused and become the great wall of steel
On 16 august 2014, a joint meeting of the national council for the defence of the rights of the child and the ministry of industry and communications stated that an incentive mechanism for the voluntary use of medical equipment from the state would be established at the san aa hospital。
Nationally produced medical devices are expected to gradually replace imports, but this will take time。
At present, the chinese market for medical equipment is about 400 billion yuan, increasing at an annual rate of 20 per cent, but more than 70 per cent of high-end medical equipment is occupied by foreign enterprises. The gps (general electrical, philips and siemens) multinational enterprises have absolute market and price advantages。
It is a little comforting to note that, in the subsector of heart support, domestic products have reversed. However, there is also a risk of confusion in this area, including the risk of reliance on foreign sources for the procurement of core components。
A little stretcher, big demand
China completed its first coronary artery intervention (pci) in 1984. Between 1984 and 1996, pci was carried out by a small number of doctors in a small number of hospitals, and by 1996 more than half of the pci had been implanted. Between 1997 and 2001, pci grew at an annual rate of 30 per cent, with more than 200 hospitals operating in pci。
According to the chinese report on cardiovascular diseases 2012, approximately 290 million people suffer from cardiovascular diseases in china, with 3. 5 million deaths per year. This group has increased significantly in recent years compared with previous years。
The implantation of support frames is one of the common methods of clinical treatment for cardiovascular diseases. Statistics from the china medical surgery emplacement board show that there were 20,000 pci cases in 2000 and 400,000 in 2011. The market has great potential, based on an average of about 1. 6 racks per operation。
Some of the most frequently cited data from heart support companies are: at present, there are more than 2 million pci cases per year and more than 3. 2 million stand-up systems worldwide; and nearly 400,000 pci cases per year in china, but nearly 95 per cent of the patients with myocardial infarction are not treated effectively. Compared to the united states and japan, there is much room for growth in the number of pci cases completed annually in china。
Although pci has developed several generations of products, there are risks such as a narrower frame and a hemorrhagic embolism, it appears that the heart support in the chinese market is already being consumed. As the ageing of society accelerates, pci cases will increase every year。
Following the new medical care, the primary health-care market was expanded, and the ministry of health allowed the level ii hospital to operate the pci, and the medical equipment enterprise began to expand to the grass-roots level. Helping grass-roots hospitals to set up intervention catheters, providing diagnostic equipment such as an angiograms, and even connecting specialists at the tertiary hospitals? A number of medical equipment companies have begun to occupy the market for basic hospitals in depth。
However, it has been alleged that about 20 per cent of patients actually need intervention. China has a strict definition of the pci adaptation certificate, but has not been able to contain a 30 per cent annual high rate of growth in support of the stand。
The existence of overmedicine
The transformation of coronary heart disease from a suspected serious disease to a highly curable disease is undoubtedly a leap forward in which heart bridging and heart intervention are essential. However, over-medicine, especially the abuse of new technologies and products, exists globally。
On 10 march 2010, the clinical medicine magazine new england medical journal reported that nearly half of patients in the united states who should not have had a heart support had been released。
Mr. Hu, member of the board of directors of the cardiovascular pathology branch of the chinese medical association, said that china was not more optimistic than the united states about the abuse of the heart support. Half of the heart stretches are not reliable, and some products have windfalls of up to nine times. Few patients abroad require more than three stairwells, but it is common in the country to have 5-10 stairwells, which are abused and become the “great wall of steel”。
In addition to the oversurgery of the plastic surgery, there is a potential for illegal sales and illegal surgery by doctors without surgical qualifications。
So the heart stretcher began to be questioned. In 2013, beijing city launched a three-month special inspection to “regulate the use of large equipment and high-value materials”。
Squeeze the price
The market for the domestic coronal artery system was dominated by foreign firms around 2004, with the cost of each case falling to around $18,000 in 2009 and falling further over the years。
The main advantage of the national shelf is its price, with patients using it saving around one third of the cost of medical equipment compared to foreign products. Foreign products have thus long been concentrated in front-line urban markets such as beijing, shanghai and guangzhou, while national production has broken through in small cities and grass-roots hospitals。
There is a grey trade in the current health-care system and the huge marketing costs of the middle links are passed on to patients. According to salesmen, “we usually leave hospitals and doctors at the highest level of 45 per cent in return”
This has resulted in current prices being considered too high. In 2013, the central leadership asked about the overprice of high-value medical consumables, including cardiac support。
A series of policies and statements by the central authorities and local governments on medical devices have since become clearer. In early 2013, for example, the central six sectors issued the code of practice for the central purchase of high-value medical consumption materials (preliminary) (hereinafter referred to as " the code " ), which clearly stipulates that all high-value medical materials must be procured centrally。
This measure directly lowers the price of the cardiac support。
The executive of a listed company with a major heart support in the country said to the east watch weekly: “the current price of foreign companies before entering the hospital is between $17 and $19,000, and the national production is only about $9,000. In particular, now that the provinces are centrally bidding for procurement, prices have been cut by about 10 per cent.”
The strength of domestic production is not strong
“nationally produced stand products still lack experience in the control of their core processes and are at the `test error' stage, and differences in product nuances have not been fully understood, resulting in an improved quality of products.” the director of the medical and armaments department of the health care chamber of china (12. 15, 0. 13, 1. 08 per cent) said to the journalist。
Http://d1. Sina. Com. Cn/pfpghc/85aec86710a945f69d00b6b31412e596. Png
Medical devices are naturally monopolistic, and it is difficult for those who come to terms with them without a breakthrough in innovative technologies. At the same time, the upgrading of new technologies will have a significant impact on existing market patterns, as some foreign firms may opt out of the process of developing or acquiring innovative products and re-killing them as they fail to upgrade their products as expected, or as their profits decline。
Since 2003 when johnson and johnson took the lead in listing the first drug release artery in the united states, sales grew sharply, reaching a global peak of $5. 1 billion in 2005. In 2006, the pharmaceutical release artery strangulations, represented by the production of strong products, quickly replaced the traditional metal strangulations, occupying 89 per cent of the global market share。
On the whole, there are still gaps in the technology of the national shelf in relation to drug and vector selection, release techniques and processes such as polishing, drug coating, etc., compared to similar products abroad. However, the national shelf is more responsive to the clinical needs of patients in the country with regard to the design, size, operational convenience and integration of the support and delivery systems。
Show the rest of the previous page 12 next page on this page
